Objective: To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE).
Design: Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014-ongoing).
Setting: Seventy-six centres in France.